



Atracurium Kalceks

10 mg/mL

solution for injection/infusion

Atracurium besylate is highly selective, competitive or non-depolarising blocking agent of neuromuscular transmission used in addition to other medications to provide skeletal muscle relaxation during surgery or mechanical ventilation. The time of onset is approximately 2-3 minutes for atracurium, duration of action is 45 minutes¹.

Nowadays Atracurium can be used as a relaxing agent of skeletal muscles to facilitate tracheal intubation/mechanical ventilation in the treatment of very low lung compliance associated with COVID-19 infection².

Approved:

- By the Food and Drug Administration (FDA) on June 20, 1985;
- In UK in 1983.
- Registration in Malaysia in 2021.

Indications:

Atracurium is a highly selective, competitive or non-depolarising neuromuscular blocking agent which is used as an adjunct to general anaesthesia to enable tracheal intubation to be performed and to relax skeletal muscles during surgery or controlled ventilation, and to facilitate mechanical ventilation in Intensive Care Unit (ICU) patients.

Atracurium advantages in comparison with other non-depolarizing neuromuscular blocking agents:

- The binding action is easily reversed by anti-cholinesterase agents³.
- The use of Atracurium during mechanical ventilation in patients with acute respiratory distress syndrome (ARDS) improves respiratory support conditions and reduces mortality. In the context of COVID-19 pandemic, patients with severe forms of the disease hospitalized in intensive care units (ICU) benefit from prolonged mechanical ventilation with frequent use of Atracurium².

Atracurium Kalceks 10 mg/mL solution for injection/infusion available:

2.5 ml of solution filled in 5.0ml type I colourless borosilicate glass ampoules with one point cut.

Product shelf life – Unopened ampoule: 2 years.

After opening the ampoule: Once opened, the product should be used immediately.

Special precautions for storage

Store and transport refrigerated (2°C - 8°C). Do not freeze.
Store in the original package in order to protect from light.

Pack sizes:

5 ampoules of 2.5 ml.

Refer package insert for further information.

¹ Mims. n.d.

² Ammar, MA, et al. Sedation, Analgesia, and Paralysis in COVID-19 Patients in the Setting of Drug Shortages. J Intensive Care Med. 2021 36(2): 157–174.

³ Prielipp RC, Coursin DB, Scuderi PE, Bowton DL, Ford SR, Cardenas VJ, Vender J, Howard D, Casale EJ, Murray MJ. Anesth. Analg. 1995 Jul;81(1):3-12.